Prospective associations of blood-based biomarkers of neurodegenerative diseases with cognitive performance in a cohort of patients with chronic coronary syndrome
Restricted accessResearch articleFirst published online December, 2025
Prospective associations of blood-based biomarkers of neurodegenerative diseases with cognitive performance in a cohort of patients with chronic coronary syndrome
In a cohort of persons with chronic coronary syndrome, we investigated associations of blood-based biomarkers of neurodegenerative diseases with cognitive scores and mild cognitive impairment (MCI) after ten years. Biomarker levels were measured in baseline samples of serum (glial fibrillary acid protein, neurofilament light chain (NfL), phosphorylated tau181; n = 363) or plasma (amyloid-β42/40-ratio, total-tau; n = 232). Cognitive scores and MCI were measured at ten-year follow-up using the Cognitive Telephone Screening Instrument. At follow-up, 14.7% had MCI. The amyloid-β42/40-ratio was predictive of cognitive scores, while NfL was associated with increased risk of MCI, suggesting that these biomarkers might be utilized for risk stratification.
GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health2022; 7: e105–e125.
2.
DeckersKSchievinkSHJRodriquezMMF, et al.Coronary heart disease and risk for cognitive impairment or dementia: systematic review and meta-analysis. PLoS One2017; 12: e0184244.
3.
CasserlyITopolEJ. Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet2004; 363: 1139–1146.
4.
van NieuwkerkACDelewiRWoltersFJ, et al.Cognitive impairment in patients with cardiac disease: implications for clinical practice. Stroke2023; 54: 2181–2191.
5.
StakosDAStamatelopoulosKBampatsiasD, et al.The Alzheimer's disease amyloid-beta hypothesis in cardiovascular aging and disease: JACC focus seminar. J Am Coll Cardiol2020; 75: 952–967.
6.
ChenG-fXuT-hYanY, et al.Amyloid beta: structure, biology and structure-based therapeutic development. Acta Pharmacol Sin2017; 38: 1205–1235.
7.
HardyJSelkoeDJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science2002; 297: 353–356.
8.
LiDMielkeMM. An update on blood-based markers of Alzheimer's disease using the SiMoA platform. Neurol Ther2019; 8: 73–82.
9.
StockerHBeyerLPernaL, et al.Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: results from a prospective cohort followed over 17 years. Alzheimers Dement2023; 19: 25–35.
10.
LohnerVPernaLSchöttkerB, et al.Associations of blood-based biomarkers of neurodegenerative diseases with mortality, cardio- and cerebrovascular events in persons with chronic coronary syndrome. Exp Gerontol2025; 200: 112684.
11.
MoscosoAGrotheMJAshtonNJ, et al.Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol2021; 78: 396–406.
12.
VerberkIMWLaarhuisMBvan den BoschKA, et al.Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. Lancet Healthy Longev2021; 2: e87–e95.
13.
de WolfFGhanbariMLicherS, et al.Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study. Brain2020; 143: 1220–1232.
14.
MonsUHahmannHBrennerH. A reverse J-shaped association of leisure time physical activity with prognosis in patients with stable coronary heart disease: evidence from a large cohort with repeated measurements. Heart2014; 100: 1043–1049.
15.
KliegelMMartinMJägerT. Development and validation of the Cognitive Telephone Screening Instrument (COGTEL) for the assessment of cognitive function across adulthood. J Psychol2007; 141: 147–170.
16.
AlexopoulosPSkondraMKontogianniE, et al.Validation of the cognitive telephone screening instruments COGTEL and COGTEL+ in identifying clinically diagnosed neurocognitive disorder due to Alzheimer's disease in a naturalistic clinical setting. J Alzheimers Dis2021; 83: 259–268.
17.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2020.
18.
StekhovenDJBühlmannP. Missforest—non-parametric missing value imputation for mixed-type data. Bioinformatics2011; 28: 112–118.
19.
JanelidzeSZetterbergHMattssonN, et al.CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. Ann Clin Transl Neurol2016; 3: 154–165.
20.
GiudiciKVde Souto BarretoPGuyonnetS, et al.Assessment of plasma amyloid-β42/40 and cognitive decline among community-dwelling older adults. JAMA Netw Open2020; 3: e2028634.
21.
Graff-RadfordNRCrookJELucasJ, et al.Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol2007; 64: 354–362.
22.
PalmqvistSJanelidzeSStomrudE, et al.Performance of fully automated plasma assays as screening tests for Alzheimer disease–related β-amyloid status. JAMA Neurol2019; 76: 1060–1069.
23.
KhalilMTeunissenCEOttoM, et al.Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol2018; 14: 577–589.
24.
WangXShiZQiuY, et al.Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank. BMC Med2024; 22: 192.
25.
MattssonNCullenNCAndreassonU, et al.Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol2019; 76: 791–799.
26.
CronjéHTLiuXOddenMC, et al.Serum NfL and GFAP are associated with incident dementia and dementia mortality in older adults: the cardiovascular health study. Alzheimers Dement2023; 19: 5672–5680.
27.
ZetterbergHBendlinBB. Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. Mol Psychiatry2021; 26: 296–308.
28.
ZlokovicBV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci2011; 12: 723–738.
KhalilMTeunissenCELehmannS, et al.Neurofilaments as biomarkers in neurological disorders—towards clinical application. Nat Rev Neurol2024; 20: 269–287.
31.
ZuoWWuJ. The interaction and pathogenesis between cognitive impairment and common cardiovascular diseases in the elderly. Ther Adv Chronic Dis2022; 13: 20406223211063020.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
